New drug shows promise in reducing lung scarring in small trial
NCT ID NCT05621252
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2a trial tested a drug called PLN-74809 in 10 people with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. Participants took the drug or a placebo daily for 12 weeks. The study used a special PET/MRI scan to measure collagen (scar tissue) in the lungs. The goal was to see if the drug could reduce scarring and to check its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PLN-74809 (a drug to reduce lung scarring)
What this could lead to
If successful, this could point toward a treatment that slows or reduces scarring in the lungs for people with idiopathic pulmonary fibrosis.
What could go wrong
This is a very small, early-phase trial with only 10 participants. It is designed mainly to test imaging and safety, not yet to prove the drug works. The drug may not show benefit or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States